The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net earnings | 3,246 | 2,993 | 3,165 | 2,358 |
| Depreciation | 461 | 427 | 393 | 371 |
| Amortization of intangible assets | 732 | 623 | 635 | 627 |
| Goodwill impairment | - | - | 0 | 216 |
| Asset impairments | - | - | 36 | 54 |
| Goodwill and other impairments | 170 | 977 | - | - |
| Share-based compensation | 243 | 229 | 205 | 168 |
| Recall charges, net | - | - | 18 | -15 |
| Sale of inventory stepped up to fair value at acquisition | 173 | 46 | - | 12 |
| Deferred income tax (benefit) expense | 392 | -370 | -206 | 58 |
| Accounts receivable | -127 | 321 | 175 | 579 |
| Inventories | 297 | 206 | 797 | 762 |
| Accounts payable | 94 | 192 | 77 | 290 |
| Accrued expenses and other liabilities | 318 | 74 | 533 | 328 |
| Recall-related payments | - | - | -35 | -157 |
| Income taxes | -145 | -116 | -4 | -238 |
| Other, net | 470 | 306 | 134 | 107 |
| Net cash provided by operating activities | 5,044 | 4,242 | 3,711 | 2,624 |
| Acquisitions, net of cash acquired | 4,960 | 1,628 | 390 | 2,563 |
| Purchase of short-term investments | - | 750 | - | - |
| Purchases of marketable securities | - | 58 | 52 | 52 |
| Proceeds from sales of marketable securities | - | 49 | 54 | 43 |
| Proceeds/(purchases) of short-term investments | -750 | - | - | - |
| Purchases of property, plant and equipment | 761 | 755 | 575 | 588 |
| Proceeds from settlement of net investment hedges | - | 99 | 0 | 197 |
| Proceeds from the sale of the spinal implants business | 165 | - | - | - |
| Other investing, net | 60 | -43 | -1 | -39 |
| Net cash used in investing activities | -4,866 | -3,000 | -962 | -2,924 |
| Proceeds (payments) on short-term borrowings, net | 0 | -32 | 540 | -375 |
| Proceeds from issuance of long-term debt | 2,979 | 3,011 | 1,241 | 1,500 |
| Payments on long-term debt | 1,400 | 2,039 | 2,058 | 653 |
| Payments of dividends | 1,284 | 1,219 | 1,139 | 1,051 |
| Cash paid for taxes from withheld shares | 149 | 195 | 155 | 122 |
| Other financing, net | -33 | -51 | -23 | -48 |
| Net cash provided by (used in) financing activities | 113 | -525 | -1,594 | -749 |
| Effect of exchange rate changes on cash and cash equivalents | 68 | -36 | -28 | -51 |
| Change in cash and cash equivalents | 359 | 681 | 1,127 | -1,100 |
| Cash and cash equivalents at beginning of period | 3,652 | 2,971 | 1,844 | 2,944 |
| Cash and cash equivalents at end of period | 4,011 | 3,652 | 2,971 | 1,844 |
STRYKER CORP (SYK)
STRYKER CORP (SYK)